464 related articles for article (PubMed ID: 36389763)
1. Identification and validation of immunotherapy for four novel clusters of colorectal cancer based on the tumor microenvironment.
Zheng X; Ma Y; Bai Y; Huang T; Lv X; Deng J; Wang Z; Lian W; Tong Y; Zhang X; Yue M; Zhang Y; Li L; Peng M
Front Immunol; 2022; 13():984480. PubMed ID: 36389763
[TBL] [Abstract][Full Text] [Related]
2. Immune depletion of the methylated phenotype of colon cancer is closely related to resistance to immune checkpoint inhibitors.
Zhong C; Xie T; Chen L; Zhong X; Li X; Cai X; Chen K; Lan S
Front Immunol; 2022; 13():983636. PubMed ID: 36159794
[TBL] [Abstract][Full Text] [Related]
3. Tumor microenvironment characterization in colorectal cancer to identify prognostic and immunotherapy genes signature.
Guo XW; Lei RE; Zhou QN; Zhang G; Hu BL; Liang YX
BMC Cancer; 2023 Aug; 23(1):773. PubMed ID: 37596528
[TBL] [Abstract][Full Text] [Related]
4. Computational identification and clinical validation of a novel risk signature based on coagulation-related lncRNAs for predicting prognosis, immunotherapy response, and chemosensitivity in colorectal cancer patients.
Zhang F; Zhang R; Zong J; Hou Y; Zhou M; Yan Z; Li T; Gan W; Lv S; Yang L; Zeng Z; Zhao W; Yang M
Front Immunol; 2023; 14():1279789. PubMed ID: 37928532
[TBL] [Abstract][Full Text] [Related]
5. Development of a novel hypoxia-immune-related LncRNA risk signature for predicting the prognosis and immunotherapy response of colorectal cancer.
Luan L; Dai Y; Shen T; Yang C; Chen Z; Liu S; Jia J; Li Z; Fang S; Qiu H; Cheng X; Yang Z
Front Immunol; 2022; 13():951455. PubMed ID: 36189298
[TBL] [Abstract][Full Text] [Related]
6. Integrated single-cell and bulk RNA sequencing analysis identifies a cancer associated fibroblast-related signature for predicting prognosis and therapeutic responses in colorectal cancer.
Zheng H; Liu H; Ge Y; Wang X
Cancer Cell Int; 2021 Oct; 21(1):552. PubMed ID: 34670584
[TBL] [Abstract][Full Text] [Related]
7. Cross-Talk Between m
Song W; Ren J; Xiang R; Yuan W; Fu T
Front Immunol; 2022; 13():740960. PubMed ID: 35350786
[TBL] [Abstract][Full Text] [Related]
8. Characterization of stem cell landscape and identification of stemness-relevant prognostic gene signature to aid immunotherapy in colorectal cancer.
Zheng H; Liu H; Li H; Dou W; Wang J; Zhang J; Liu T; Wu Y; Liu Y; Wang X
Stem Cell Res Ther; 2022 Jun; 13(1):244. PubMed ID: 35681225
[TBL] [Abstract][Full Text] [Related]
9. Interferon regulatory factor family influences tumor immunity and prognosis of patients with colorectal cancer.
Chen YJ; Luo SN; Dong L; Liu TT; Shen XZ; Zhang NP; Liang L
J Transl Med; 2021 Sep; 19(1):379. PubMed ID: 34488791
[TBL] [Abstract][Full Text] [Related]
10. Tumor microenvironment-related gene selenium-binding protein 1 (SELENBP1) is associated with immunotherapy efficacy and survival in colorectal cancer.
Zhu C; Wang S; Du Y; Dai Y; Huai Q; Li X; Du Y; Dai H; Yuan W; Yin S; Wang H
BMC Gastroenterol; 2022 Oct; 22(1):437. PubMed ID: 36253721
[TBL] [Abstract][Full Text] [Related]
11. Identification of Genes Related to 5-Fluorouracil Based Chemotherapy for Colorectal Cancer.
Huang X; Ke K; Jin W; Zhu Q; Zhu Q; Mei R; Zhang R; Yu S; Shou L; Sun X; Feng J; Duan T; Mou Y; Xie T; Wu Q; Sui X
Front Immunol; 2022; 13():887048. PubMed ID: 35784334
[TBL] [Abstract][Full Text] [Related]
12. Identification and validation of pyroptosis-related gene landscape in prognosis and immunotherapy of ovarian cancer.
Gao L; Ying F; Cai J; Peng M; Xiao M; Sun S; Zeng Y; Xiong Z; Cai L; Gao R; Wang Z
J Ovarian Res; 2023 Jan; 16(1):27. PubMed ID: 36707884
[TBL] [Abstract][Full Text] [Related]
13. Multi-omics cluster defines the subtypes of CRC with distinct prognosis and tumor microenvironment.
Ma Y; Li J; Zhao X; Ji C; Hu W; Ma Y; Qu F; Sun Y; Zhang X
Eur J Med Res; 2024 Mar; 29(1):207. PubMed ID: 38549156
[TBL] [Abstract][Full Text] [Related]
14. Neutrophil extracellular traps-associated modification patterns depict the tumor microenvironment, precision immunotherapy, and prognosis of clear cell renal cell carcinoma.
Teng ZH; Li WC; Li ZC; Wang YX; Han ZW; Zhang YP
Front Oncol; 2022; 12():1094248. PubMed ID: 36620592
[TBL] [Abstract][Full Text] [Related]
15. Single-cell N
Gao Y; Wang H; Chen S; An R; Chu Y; Li G; Wang Y; Xie X; Zhang J
J Transl Med; 2022 May; 20(1):197. PubMed ID: 35509079
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive pan-cancer analysis of role of GPRASP1, associated with clinical outcomes, immune microenvironment, and immunotherapeutic efficiency in pancreatic cancer.
Du J; Chen Y; Liu G; Zeng Q; Zhou N; Du D
Pathol Res Pract; 2023 Mar; 243():154374. PubMed ID: 36801507
[TBL] [Abstract][Full Text] [Related]
17. Cancer-associated fibroblast-related gene signatures predict survival and drug response in patients with colorectal cancer.
Zhang L; Xu C; Wang SH; Ge QW; Wang XW; Xiao P; Yao QH
Front Genet; 2022; 13():1054152. PubMed ID: 36506313
[No Abstract] [Full Text] [Related]
18. Integrated Profiling Identifies
Shi J; Bao M; Wang W; Wu X; Li Y; Zhao C; Liu W
Front Immunol; 2021; 12():722807. PubMed ID: 34646265
[TBL] [Abstract][Full Text] [Related]
19. An immune-related gene prognostic index for predicting prognosis in patients with colorectal cancer.
Li C; Wirth U; Schardey J; Ehrlich-Treuenstätt VV; Bazhin AV; Werner J; Kühn F
Front Immunol; 2023; 14():1156488. PubMed ID: 37483596
[TBL] [Abstract][Full Text] [Related]
20. SPARCL1 Is a Novel Prognostic Biomarker and Correlates with Tumor Microenvironment in Colorectal Cancer.
Zhang HP; Wu J; Liu ZF; Gao JW; Li SY
Biomed Res Int; 2022; 2022():1398268. PubMed ID: 35111844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
